A biomarker study in Peruvian males with breast cancer

Table 1 Clinical-pathological features and overall survival impact in male breast cancer

Features	n	%	OS-5yr	P value
Age
Median (yr)	63			0.105a
< 63	25	53.7	56.0
≥ 63	29	46.3	69.0
Clinical stage (n = 53)				< 0.001a
I	2	3.8	100.0
II	22	41.5	86.4
III	20	37.7	50.0
IV	9	17.0	22.2
Histological grade (n = 46)				0.006a
1	7	15.2	85.7
2	26	56.5	73.1
3	13	28.3	30.8
sTIL (n = 42)				0.397b
< 10%	12	28.6	50.0
≥ 10%	30	71.4	66.7
ER status (n = 49)				0.567a
Positive	42	85.7	66.7
Negative	7	14.3	57.1
PgR status (n = 49)				0.305a
Positive	43	87.8	67.4
Negative	6	12.2	50.0
HER2 status (n = 47)				0.088b
Positive	6	12.8	33.3
Negative	41	87.2	70.7
Ki67 (n = 40) (median 5%)				0.232a
0%-5%	22	55.0	59.1
> 5%	18	45.0	66.7
Phenotype (n = 45)				0.356a
Luminal A	27	60.0	63.0
Luminal B	13	28.9	76.9
TNBC	5	11.1	40.0
AR (n = 35)				0.294a
0%-9%	5	14.3	60.0
≥ 10%	30	85.7	63.3
Mismatch repair loss (n = 26)				0.501a
No	20	76.9	65.00
Yes	4	15.4	75.00
Undetermined	2	7.7	100.00
PIK3CA mutation H1047R (n = 14)				0.844b
Positive	2	14.3	50.0
Negative	12	85.7	75.0

^aP: Breslow.

^bP: Log Rank. OS: Overall survival; TIL: Tumor infiltrating lymphocyte; TNBC: Triple negative breast cancer.